| Identification | Back Directory | [Name]
Bevirimat | [CAS]
174022-42-5 | [Synonyms]
BVM
PA-457
CS-1322
MPC-4326
FH 11327
Bevirimat
Bevirimat, >99%
Bevirimat(PA-457)
BVM; MPC-4326; PA-457
Bevirimat 174022-42-5
Bevirimat, PA 457, FH 312
PA-457; MPC-4326; FH11327; YK FH312
O-(3,3-Dimethylsuccinyl)betulinic acid
Lup-20(29)-en-28-oic acid, 3-(3-carboxy-3-methyl-1-oxobutoxy)-, (3β)- | [Molecular Formula]
C36H56O6 | [MDL Number]
MFCD00954243 | [MOL File]
174022-42-5.mol | [Molecular Weight]
584.83 |
| Chemical Properties | Back Directory | [Melting point ]
>263°C (dec.) | [Boiling point ]
662.7±40.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Acetonitrile (Slightly), Methanol (Very Slightly, Heated, Sonicated) | [form ]
Solid | [pka]
4.48±0.28(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
YJEJKUQEXFSVCJ-WRFMNRASSA-N | [SMILES]
CC([C@H]1[C@]2([H])[C@@]3([H])CC[C@@]4([H])[C@](CC[C@]5([H])[C@]4(C)CC[C@H](OC(CC(C)(C(O)=O)C)=O)C5(C)C)(C)[C@]3(C)CC[C@@]2(C(O)=O)CC1)=C |
| Hazard Information | Back Directory | [Description]
PA-457 is an inhibitor of HIV-1 virion maturation.1,2 It inhibits the cleavage of the Gag capsid (CA) precursor CA-SP1 to the mature CA protein. PA-457 inhibits the replication of drug-sensitive and -resistant clinical isolates of HIV-1 in isolated human peripheral blood mononuclear cells (PBMCs; mean IC50s = 10.3 and 7.8 nM, respectively).3 In vivo, it prevents replication of HIV-1 in SCID-hu Thy/Liv mice when administered at a dose of 100 mg/kg.4 | [Chemical Properties]
White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents. | [Uses]
Bevirimat is a HIV-1 maturation inhibitor, targetting the Gag CA-SP1 cleavage site. HIV Inhibitor. | [Definition]
ChEBI: A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhib
tors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems. | [Enzyme inhibitor]
This first-in-class, natural product-based antiviral (FW = 584.83 g/mol; CAS 174022-42-5; Abbreviation: BVM), also known as 3-O-(3',3'- dimethylsuccinyl)betulinate (DSB), 3β-(3-carboxy-3-methyl-butanoyloxy)- lup-20(29)-en-28-oic acid, PA-457, and MPC-4326, is a novel HIV-1 maturation inhibitor that blocks proteolytic processing of the Gag capsid precursor (CA-SP1) into mature capsid (CA) protein. Bevirimat binds to the Gag polypeptide at the CA/SP1 cleavage site. The net result of BVM treatment is the release of immature, noninfectious viral particles. Despite its promising mode of action, about half of all patients have viruses containing genetic polymorphisms in the Gag SP1 (at positions 6 to 8) protein do not respond to BVM treatment. | [target]
HIV | [storage]
Store at -20°C | [References]
[1] DAVID E MARTIN Graham P A Karl Salzwedel. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.[J]. Antiviral Chemistry and Chemotherapy, 2008, 19 3: 107-113. DOI: 10.1177/095632020801900301
[2] DAN WANG Feng L Wuxun Lu. Pharmacological intervention of HIV-1 maturation[J]. Acta Pharmaceutica Sinica. B, 2015, 5 6: Pages 493-499. DOI: 10.1016/j.apsb.2015.05.004
[3] F LI. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100 23: 13555-13560. DOI: 10.1073/pnas.2234683100
[4] CHERYL A STODDART. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.[J]. PLoS ONE, 2007: e1251. DOI: 10.1371/journal.pone.0001251 |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|